ReproCELL

Executive Summary

ReproCELL is a global preclinical and clinical research company that provides products and services to accelerate the translation of stem cell and drug discovery research into therapies. Based in Glasgow, UK, the company offers a comprehensive portfolio including stem cell reprogramming kits, iPSC lines, GMP manufacturing, 3D tissue engineering platforms, and human tissue-based contract research services. Its solutions are used by scientists worldwide to bridge the gap between preclinical models and human clinical trials. Founded in 2003, ReproCELL is privately held and has established a strong presence in the antibodies and stem cell research categories.

Upcoming Catalysts (preview)

• Q3 2026Launch of new disease-specific iPSC lines for neurological disorders70% success
• H2 2026Strategic partnership with a top 20 pharmaceutical company for drug discovery services50% success
• 2026Expansion of GMP manufacturing capacity to serve cell therapy clients60% success